Technical Data
H2005-07A
Hepatocyte Growth Factor, Recombinant, Human (HGF, HGFB, DFNB39, F-TCF, Hepatopoeitin-A, HPTA, Scatter Factor, SF)
2ug
|
Technical Data |
|
H2005-07A |
Hepatocyte Growth Factor, Recombinant, Human (HGF, HGFB, DFNB39, F-TCF, Hepatopoeitin-A, HPTA, Scatter Factor, SF) |
2ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 463aa of human Hepatocyte Growth Factor expressed in Baculovirus is a heterodimer, non-glycosylated, polypeptide chain. Molecular Weight: ~80kD Biological Activity: The ED50, calculated by the dose-dependent proliferation of monkey 4MBr-5 indicator cells was found to be 20-40nug/ml Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1.UV spectroscopy at 280nm using the absorbency value of 1.83 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of HGF as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~80kD |
Source: Baculovirus Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: Not determined Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Kidney volume and plasma hepatocyte growth factor-transforming growth factor beta1 ratio among children with biliary atresia before and after liver transplantation: the reversibility of nephromegaly. Am J Kidney Dis 2005 Nov;46( 5):830-6. 2. Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg 2005 Nov;242(5):676-83. 3. Arginine-specific gingipains from Porphyromonas gingivalis stimulate production of hepatocyte growth factor (scatter factor) through protease-activated receptors in human gingival fibroblasts in culture. J Immunol 2005 Nov 1;175(9):6076-84. 4. Generation of inhibitory DNA aptamers against human hepatocyte growth factor. DNA Cell Biol 2005 Oct;24(10):624-33. 5. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology 2005 Sep-Oct;52(65):1393-7. 6. [Development of an innovative therapy for inflammatory bowel disease using recombinant human hepatocyte growth factor to facilitate intestinal mucosal repair]. Nippon Shokakibyo Gakkai Zasshi 2005 Sep;102(9):1139-45.
|
||